- Home
- BMEA vs ACB Comparison
BMEA vs ACB Comparison
Compare BMEA & ACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- ACB
- Stock Information
- Founded
- BMEA 2017
- ACB 2013
- Country
- BMEA United States
- ACB Canada
- Employees
- BMEA N/A
- ACB N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- ACB Pharmaceuticals and Biotechnology
- Sector
- BMEA Health Care
- ACB Health Care
- Exchange
- BMEA Nasdaq
- ACB Nasdaq
- Market Cap
- BMEA 275.6M
- ACB 315.4M
- IPO Year
- BMEA 2021
- ACB N/A
- Fundamental
- Price
- BMEA $11.24
- ACB $5.51
- Analyst Decision
- BMEA Buy
- ACB Hold
- Analyst Count
- BMEA 13
- ACB 1
- Target Price
- BMEA $36.33
- ACB N/A
- AVG Volume (30 Days)
- BMEA 1.1M
- ACB 659.5K
- Earning Date
- BMEA 11-01-2024
- ACB 11-07-2024
- Dividend Yield
- BMEA N/A
- ACB N/A
- EPS Growth
- BMEA N/A
- ACB N/A
- EPS
- BMEA N/A
- ACB N/A
- Revenue
- BMEA N/A
- ACB $203,838,819.00
- Revenue This Year
- BMEA N/A
- ACB $14.04
- Revenue Next Year
- BMEA N/A
- ACB $8.94
- P/E Ratio
- BMEA N/A
- ACB N/A
- Revenue Growth
- BMEA N/A
- ACB 12.30
- 52 Week Low
- BMEA $3.61
- ACB $2.84
- 52 Week High
- BMEA $22.74
- ACB $9.35
- Technical
- Relative Strength Index (RSI)
- BMEA 64.18
- ACB 46.80
- Support Level
- BMEA $10.35
- ACB $5.46
- Resistance Level
- BMEA $12.30
- ACB $5.66
- Average True Range (ATR)
- BMEA 0.93
- ACB 0.17
- MACD
- BMEA -0.01
- ACB 0.03
- Stochastic Oscillator
- BMEA 47.26
- ACB 71.15
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.
About ACB Aurora Cannabis Inc.
Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements.